Spots Global Cancer Trial Database for mss
Every month we try and update this database with for mss cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | NCT05954429 | Colorectal Canc... | serplulimab Fruquintinib | 18 Years - | Fudan University | |
| Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | NCT03007407 | Colorectal Canc... | durvalumab Tremelimumab | 18 Years - | NSABP Foundation Inc | |
| Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer | NCT05933980 | Colorectal Canc... Liver Metastase... MSS | Rego+Tori+Cele | 18 Years - 100 Years | Sun Yat-sen University | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab | NCT06415851 | Metastatic Colo... MSS | mFOLFOX6 regime... | 18 Years - 75 Years | Sir Run Run Shaw Hospital | |
| A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | NCT05954429 | Colorectal Canc... | serplulimab Fruquintinib | 18 Years - | Fudan University | |
| Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers | NCT05582031 | Anal Squamous C... Colorectal Neop... Soft Tissue Sar... Malignant Pleur... Small Cell Lung... Castrate Resist... Neuroendocrine ... Gastroenteropan... | Regorafenib in ... | 18 Years - | Translational Research in Oncology | |
| Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer | NCT04046445 | Colorectal Canc... MSS Stage IV Colon ... Stage IV Rectal... Metastatic Colo... Liver Metastasi... | ATP128 BI 754091 VSV-GP128 | 18 Years - | Amal Therapeutics | |
| Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | NCT03711058 | Unresectable or... Colon Cancer | Copanlisib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer | NCT05933980 | Colorectal Canc... Liver Metastase... MSS | Rego+Tori+Cele | 18 Years - 100 Years | Sun Yat-sen University | |
| Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | NCT03271047 | MSS RAS-mutant Colo... | binimetinib nivolumab ipilimumab | 18 Years - | Pfizer | |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer | NCT06268015 | Colorectal Canc... | Botensilimab Balstilimab Oxaliplatin Leucovorin Fluorouracil Bevacizumab Panitumumab | 18 Years - | Duke University | |
| Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer | NCT04030260 | Colorectal Canc... MSS | Regorafenib and... Radiation thera... | 18 Years - 70 Years | Sun Yat-sen University | |
| Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC | NCT03274804 | Metastatic Colo... MSS | Pembrolizumab Maraviroc | 18 Years - | University Hospital Heidelberg | |
| Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC | NCT03274804 | Metastatic Colo... MSS | Pembrolizumab Maraviroc | 18 Years - | University Hospital Heidelberg | |
| Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | NCT06176885 | Colorectal Canc... | Camrelizumab | 18 Years - 75 Years | Jinhua Central Hospital | |
| Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC | NCT03274804 | Metastatic Colo... MSS | Pembrolizumab Maraviroc | 18 Years - | University Hospital Heidelberg | |
| Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | NCT05243862 | Colorectal Canc... | PolyPEPI1018 Atezolizumab | 18 Years - | Treos Bio Limited | |
| Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | NCT03102047 | Rectal Cancer | durvalumab | 18 Years - | NSABP Foundation Inc | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours | NCT02521844 | Solid Tumors | ETC-1922159 Pembrolizumab | 18 Years - | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | |
| A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | NCT05167409 | Microsatellite ... | Evorpacept (ALX... Cetuximab Pembrolizumab | 18 Years - | University of Colorado, Denver | |
| Study to Evaluate the Efficacy and Safety of Cetuximab in Combination With Encorafenib Plus Binimetinib as Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer | NCT06207656 | Colorectal Canc... | EBC | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | NCT05733611 | Refractory Meta... pMMR MSS | RP2 RP3 atezolizumab bevacizumab | 18 Years - | Replimune Inc. | |
| Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer | NCT05877573 | Locally Advance... High-Risk Rectal Cancer MSS | Toripalimab short-term radi... Oxaliplatin Capecitabine | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | NCT05954429 | Colorectal Canc... | serplulimab Fruquintinib | 18 Years - | Fudan University | |
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer | NCT03832621 | Metastatic Colo... | Temozolomide Nivolumab Ipilimumab | 18 Years - 99 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | NCT05815303 | Rectal Cancer MSS | Cadonilimab Oxaliplatin Capecitabine | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | NCT05608044 | Metastatic Colo... | Botensilimab Balstilimab Standard of Car... | 18 Years - | Agenus Inc. | |
| Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer | NCT05136326 | Rectal Cancer | External-beam r... Capecitabine Temozolomide | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | NCT03642067 | Microsatellite ... Colorectal Aden... | Nivolumab Relatlimab Nivolumab Relatlimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | NCT05608044 | Metastatic Colo... | Botensilimab Balstilimab Standard of Car... | 18 Years - | Agenus Inc. | |
| Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | NCT03711058 | Unresectable or... Colon Cancer | Copanlisib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | NCT05815303 | Rectal Cancer MSS | Cadonilimab Oxaliplatin Capecitabine | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | NCT05731726 | pMMR MSS MSI-L Locally Advance... | Serplilumab Capecitabine Oxaliplatin Celecoxib | 18 Years - 75 Years | Zhejiang University | |
| Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer | NCT05136326 | Rectal Cancer | External-beam r... Capecitabine Temozolomide | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | NCT04659382 | Metastatic Colo... pMMR MSS Immune Checkpoi... Internal Radiot... | Atezolizumab Therasphere XELOX Bevacizumab | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer | NCT05933980 | Colorectal Canc... Liver Metastase... MSS | Rego+Tori+Cele | 18 Years - 100 Years | Sun Yat-sen University | |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer | NCT06268015 | Colorectal Canc... | Botensilimab Balstilimab Oxaliplatin Leucovorin Fluorouracil Bevacizumab Panitumumab | 18 Years - | Duke University | |
| A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours | NCT02521844 | Solid Tumors | ETC-1922159 Pembrolizumab | 18 Years - | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | |
| Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | NCT05731726 | pMMR MSS MSI-L Locally Advance... | Serplilumab Capecitabine Oxaliplatin Celecoxib | 18 Years - 75 Years | Zhejiang University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
